Pharvaris N.V. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was EUR 100.88 million compared to EUR 76.33 million a year ago. Basic loss per share from continuing operations was EUR 2.63 compared to EUR 2.27 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.8 USD | +4.39% |
|
-1.31% | -32.98% |
06-04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
05-09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.98% | 1.01B | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023